Bicycle therapeutics reports recent business progress and fourth quarter and full year 2024 financial results

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the fourth quarter and full year ended december 31, 2024, and provided recent corporate updates. “in 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati.
BCYC Ratings Summary
BCYC Quant Ranking